Treg Cell Therapeutic Strategies for Breast Cancer: Holistic to Local Aspects

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2024 Sep 27

PMID 39329710

Authors

Hanwen Zhang

Oliver Felthaus

Andreas Eigenberger

Silvan Klein

Lukas Prantl

Affiliations

Soon will be listed here.

Abstract

Regulatory T cells (Tregs) play a key role in maintaining immune homeostasis and preventing autoimmunity through their immunosuppressive function. There have been numerous reports confirming that high levels of Tregs in the tumor microenvironment (TME) are associated with a poor prognosis, highlighting their role in promoting an immunosuppressive environment. In breast cancer (BC), Tregs interact with cancer cells, ultimately leading to the suppression of immune surveillance and promoting tumor progression. This review discusses the dual role of Tregs in breast cancer, and explores the controversies and therapeutic potential associated with targeting these cells. Researchers are investigating various strategies to deplete or inhibit Tregs, such as immune checkpoint inhibitors, cytokine antagonists, and metabolic inhibition. However, the heterogeneity of Tregs and the variable precision of treatments pose significant challenges. Understanding the functional diversity of Tregs and the latest advances in targeted therapies is critical for the development of effective therapies. This review highlights the latest approaches to Tregs for BC treatment that both attenuate Treg-mediated immunosuppression in tumors and maintain immune tolerance, and advocates precise combination therapy strategies to optimize breast cancer outcomes.

References

Zhu Q, Yuan J, He Y, Hu Y . The Effect of on Macrophage Polarization and T Cell Immunity by Targeting in Breast Cancer. J Oncol. 2021; 2021:5170496. PMC: 8514911. DOI: 10.1155/2021/5170496. View

Feuerer M, Hill J, Mathis D, Benoist C . Foxp3+ regulatory T cells: differentiation, specification, subphenotypes. Nat Immunol. 2009; 10(7):689-95. DOI: 10.1038/ni.1760. View

Pere H, Montier Y, Bayry J, Quintin-Colonna F, Merillon N, Dransart E . A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumor immunity against self antigens. Blood. 2011; 118(18):4853-62. DOI: 10.1182/blood-2011-01-329656. View

Vignali D, Collison L, Workman C . How regulatory T cells work. Nat Rev Immunol. 2008; 8(7):523-32. PMC: 2665249. DOI: 10.1038/nri2343. View

Mariathasan S, Turley S, Nickles D, Castiglioni A, Yuen K, Wang Y . TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018; 554(7693):544-548. PMC: 6028240. DOI: 10.1038/nature25501. View

Schmidt M, Fortsch C, Schmidt M, Rau T, Fietkau R, Distel L . Circulating regulatory T cells of cancer patients receiving radiochemotherapy may be useful to individualize cancer treatment. Radiother Oncol. 2012; 104(1):131-8. DOI: 10.1016/j.radonc.2012.05.003. View

Hashemi V, Maleki L, Esmaily M, Masjedi A, Ghalamfarsa G, Namdar A . Regulatory T cells in breast cancer as a potent anti-cancer therapeutic target. Int Immunopharmacol. 2019; 78:106087. DOI: 10.1016/j.intimp.2019.106087. View

Li P, Liu C, Yu Z, Wu M . New Insights into Regulatory T Cells: Exosome- and Non-Coding RNA-Mediated Regulation of Homeostasis and Resident Treg Cells. Front Immunol. 2016; 7:574. PMC: 5138199. DOI: 10.3389/fimmu.2016.00574. View

Josefowicz S, Lu L, Rudensky A . Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol. 2012; 30:531-64. PMC: 6066374. DOI: 10.1146/annurev.immunol.25.022106.141623. View

10.

Chen L, Huang H, Zhang W, Ding F, Fan Z, Zeng Z . Exosomes Derived From T Regulatory Cells Suppress CD8+ Cytotoxic T Lymphocyte Proliferation and Prolong Liver Allograft Survival. Med Sci Monit. 2019; 25:4877-4884. PMC: 6618337. DOI: 10.12659/MSM.917058. View

11.

Topalian S, Drake C, Pardoll D . Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015; 27(4):450-61. PMC: 4400238. DOI: 10.1016/j.ccell.2015.03.001. View

12.

Nishikawa H, Koyama S . Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies. J Immunother Cancer. 2021; 9(7). PMC: 8327843. DOI: 10.1136/jitc-2021-002591. View

13.

Brett E, Duscher D, Pagani A, Daigeler A, Kolbenschlag J, Hahn M . Naming the Barriers between Anti-CCR5 Therapy, Breast Cancer and Its Microenvironment. Int J Mol Sci. 2022; 23(22). PMC: 9694078. DOI: 10.3390/ijms232214159. View

14.

Gobert M, Treilleux I, Bendriss-Vermare N, Bachelot T, Goddard-Leon S, Arfi V . Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res. 2009; 69(5):2000-9. DOI: 10.1158/0008-5472.CAN-08-2360. View

15.

Mahmood U, Hanlon A, Koshy M, Buras R, Chumsri S, Tkaczuk K . Increasing national mastectomy rates for the treatment of early stage breast cancer. Ann Surg Oncol. 2012; 20(5):1436-43. DOI: 10.1245/s10434-012-2732-5. View

16.

Tanaka T, Bai Z, Srinoulprasert Y, Yang B, Yang B, Hayasaka H . Chemokines in tumor progression and metastasis. Cancer Sci. 2005; 96(6):317-22. PMC: 11158055. DOI: 10.1111/j.1349-7006.2005.00059.x. View

17.

Demeure C, Wolfers J, Martin-Garcia N, Gaulard P, Triebel F . T Lymphocytes infiltrating various tumour types express the MHC class II ligand lymphocyte activation gene-3 (LAG-3): role of LAG-3/MHC class II interactions in cell-cell contacts. Eur J Cancer. 2001; 37(13):1709-18. DOI: 10.1016/s0959-8049(01)00184-8. View

18.

King C, Sarvetnick N . Organ-specific autoimmunity. Curr Opin Immunol. 1998; 9(6):863-71. DOI: 10.1016/s0952-7915(97)80191-4. View

19.

Leclerc M, Voilin E, Gros G, Corgnac S, de Montpreville V, Validire P . Regulation of antitumour CD8 T-cell immunity and checkpoint blockade immunotherapy by Neuropilin-1. Nat Commun. 2019; 10(1):3345. PMC: 6659631. DOI: 10.1038/s41467-019-11280-z. View

20.

Armstrong J, Chen J, Schwarzschild M, Apasov S, Smith P, Caldwell C . Gene dose effect reveals no Gs-coupled A2A adenosine receptor reserve in murine T-lymphocytes: studies of cells from A2A-receptor-gene-deficient mice. Biochem J. 2001; 354(Pt 1):123-30. PMC: 1221636. DOI: 10.1042/0264-6021:3540123. View